A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer
作者： M. Copeman , K. Lynch , N. C. Tebbutt , M. Michael , J. Zalcberg
DOI: 10.1007/S00280-012-2009-5
关键词:
摘要: Purpose Platelet-derived growth factor receptor (PDGFR) inhibition by reducing tumoral interstitial fluid pressure might increase the efficacy of chemotherapy. Imatinib inhibits PDGFR kinase activity at therapeutically relevant doses. This phase I study aimed to assess maximal tolerated dose (MTD) imatinib in combination with mFOLFOX6–bevacizumab patients advanced colorectal cancer and identify pharmacokinetic (PK) interactions toxicities.
springer.com
sci-hub.se 参考文章(46)
L Vlase, I Berindan-Neagoe, O Balacescu, C Burz, A Irimie, S E Leucuta, V Cristea, M Ursu, G Kacso, C Tanaselia, C Floares, D Pelau, N Todor, Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. ,vol. 15, pp. 263- 269 ,(2010)
Brian J. Druker, Elisabeth Buchdunger, Thomas Meyer, Marcel Müller, Nicholas B. Lydon, Helmut Mett, Jürg Zimmermann, Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative Cancer Research. ,vol. 56, pp. 100- 104 ,(1996)
Andrius Kazlauskas, H-J. Su Huang, Webster K. Cavenee, Degui Wang, Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Research. ,vol. 59, pp. 1464- 1472 ,(1999)
Rakesh K. Jain, Transport of Molecules in the Tumor Interstitium: A Review Cancer Research. ,vol. 47, pp. 3039- 3051 ,(1987)
Kristian Pietras, Increasing tumor uptake of anticancer drugs with imatinib Seminars in Oncology. ,vol. 31, pp. 18- 23 ,(2004) , 10.1053/J.SEMINONCOL.2004.03.036
Philipp le Coutre, Karl-Anton Kreuzer, Stefan Pursche, Malte v. Bonin, Traugott Leopold, Gökben Baskaynak, Bernd Dörken, Gerhard Ehninger, Oliver Ottmann, Andreas Jenke, Martin Bornhäuser, Eberhard Schleyer, Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 Cancer Chemotherapy and Pharmacology. ,vol. 53, pp. 313- 323 ,(2004) , 10.1007/S00280-003-0741-6
Tiffanie Markus, David R. Spigel, F. Anthony Greco, Mark Mainwaring, David M. Waterhouse, Charles D. Webb, John D. Hainsworth, Denise A. Yardley, Howard A. Burris, Phase II Trial of Docetaxal Plus Imatinib Mesylate in the Treatment of Patients With Metastatic Breast Cancer Clinical Breast Cancer. ,vol. 9, pp. 237- 242 ,(2009) , 10.3816/CBC.2009.N.040
Chao H. Huang, Stephen K. Williamson, Peter J. Van Veldhuizen, Chung-Tsen Hsueh, Ace Allen, Ossama Tawfik, Jo Wick, Holly Smith, Adelina M. Uypeckcuat, Matthew Mayo, Karen Kelly, Potential Role of Platelet-Derived Growth Factor Receptor Inhibition Using Imatinib in Combination with Docetaxel in the Treatment of Recurrent Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 6, pp. 372- 377 ,(2011) , 10.1097/JTO.0B013E318200F9AD
Daniela Matei, Robert E. Emerson, Jeanne Schilder, Nancy Menning, Lee Ann Baldridge, Cynthia S. Johnson, Tim Breen, John McClean, Doyle Stephens, Charles Whalen, Gregory Sutton, Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Cancer. ,vol. 113, pp. 723- 732 ,(2008) , 10.1002/CNCR.23605
J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, Rafael G. Amado, A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 672- 680 ,(2009) , 10.1200/JCO.2008.19.8135